Literature DB >> 20593991

Postoperative neurological deterioration in pediatric moyamoya disease: watershed shift and hyperperfusion.

Toshiaki Hayashi1, Reizo Shirane, Miki Fujimura, Teiji Tominaga.   

Abstract

OBJECT: Young patients with moyamoya disease frequently exhibit extensive cerebral infarction at the time of initial presentation, and even in the early postoperative period. To investigate clinical characteristics in the early postoperative period, the authors prospectively analyzed findings of MR imaging, MR angiography, and SPECT before and after surgery. The authors focused in particular on how postoperative neurological deterioration occurred.
METHODS: Between August 2005 and June 2009, 22 patients younger than 18 years of age with moyamoya disease were treated at Miyagi Children's Hospital. The mean patient age (+/- SD) was 8.58 +/- 4.55 years (range 2-17 years). Superficial temporal artery-middle cerebral artery bypass and indirect bypass of encephalosynangiosis between the brain surface and the temporal muscle, galea, and dura mater were performed in 35 hemispheres. Magnetic resonance imaging and MR angiography were performed before surgery, at 7 days postoperatively, and 3-6 months after surgery. A (123)I-isopropyl iodoamphetamine SPECT scan was also obtained pre- and postoperatively.
RESULTS: During the postoperative period, neurological deterioration was observed after 15 operations (10 cases of motor paresis, 1 of aphasia, and 4 of sensory disturbance) in 13 patients. All symptoms had resolved by the time of discharge, except in 2 patients who suffered cerebral infarction. All patients exhibited disappearance (94.3%) or reduction (5.7%) of transient ischemic attacks (TIAs) during the follow-up period. Perioperative studies revealed 2 different types of radiological findings, focal uptake decrease on SPECT indicative of cerebral ischemia due to dynamic change in cerebral hemodynamics caused by bypass flow, the so-called watershed shift, and perioperative edematous lesions on MR imaging due to cerebral hyperperfusion. The frequent occurrence of preoperative TIAs was significantly associated with watershed shift, whereas preoperative MR imaging findings and preoperative SPECT findings were not. Age at operation was the only factor significantly associated with postoperative hyperperfusion.
CONCLUSIONS: In young patients, moyamoya disease exhibits rapid progression, resulting in poor clinical outcome. The risk of postoperative neurological deterioration in very young moyamoya patients with frequent TIAs should be noted. The findings in this study showed that direct bypass is not completely safe in patients with moyamoya disease because it causes dynamic change in postoperative cerebral hemodynamics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20593991     DOI: 10.3171/2010.4.PEDS09478

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  23 in total

1.  Crossed cerebellar diaschisis as an indicator of severe cerebral hyperperfusion after direct bypass for moyamoya disease.

Authors:  Haruto Uchino; Ken Kazumata; Masaki Ito; Naoki Nakayama; Satoshi Kuroda; Kiyohiro Houkin
Journal:  Neurosurg Rev       Date:  2020-02-19       Impact factor: 3.042

2.  Poster Viewing Sessions PB01-B01 to PB03-V09.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2019-07       Impact factor: 6.200

3.  Postoperative stroke and neurological outcomes in the early phase after revascularization surgeries for moyamoya disease: an age-stratified comparative analysis.

Authors:  Yoshio Araki; Kinya Yokoyama; Kenji Uda; Fumiaki Kanamori; Michihiro Kurimoto; Yoshiki Shiba; Takashi Mamiya; Masahiro Nishihori; Takashi Izumi; Masaki Sumitomo; Sho Okamoto; Kota Matsui; Ryo Emoto; Toshihiko Wakabayashi; Shigeyuki Matsui; Atsushi Natsume
Journal:  Neurosurg Rev       Date:  2021-01-08       Impact factor: 3.042

4.  Emergency EC-IC bypass for symptomatic atherosclerotic ischemic stroke.

Authors:  Tetsuyoshi Horiuchi; Junpei Nitta; Shigetoshi Ishizaka; Kohei Kanaya; Takao Yanagawa; Kazuhiro Hongo
Journal:  Neurosurg Rev       Date:  2013-07-03       Impact factor: 3.042

5.  Uneven cerebral hemodynamic change as a cause of neurological deterioration in the acute stage after direct revascularization for moyamoya disease: cerebral hyperperfusion and remote ischemia caused by the 'watershed shift'.

Authors:  Xian-Kun Tu; Miki Fujimura; Sherif Rashad; Shunji Mugikura; Hiroyuki Sakata; Kuniyasu Niizuma; Teiji Tominaga
Journal:  Neurosurg Rev       Date:  2017-03-29       Impact factor: 3.042

6.  Long-term follow-up of pediatric moyamoya disease treated by combined direct-indirect revascularization surgery: single institute experience with surgical and perioperative management.

Authors:  Sherif Rashad; Miki Fujimura; Kuniyasu Niizuma; Hidenori Endo; Teiji Tominaga
Journal:  Neurosurg Rev       Date:  2016-05-16       Impact factor: 3.042

7.  Efficacy of superficial temporal artery-middle cerebral artery double anastomoses in a patient with rapidly progressive moyamoya disease: case report.

Authors:  Michiko Yokosawa; Toshiaki Hayashi; Reizo Shirane; Teiji Tominaga
Journal:  Neurol Med Chir (Tokyo)       Date:  2014-02-28       Impact factor: 1.742

Review 8.  Research Progress of Moyamoya Disease in Children.

Authors:  Jianmin Piao; Wei Wu; Zhongxi Yang; Jinlu Yu
Journal:  Int J Med Sci       Date:  2015-07-03       Impact factor: 3.738

9.  Preliminary study of neurocognitive dysfunction in adult moyamoya disease and improvement after superficial temporal artery-middle cerebral artery bypass.

Authors:  Hyun Joo Baek; Seung Young Chung; Moon Sun Park; Seong Min Kim; Ki Suk Park; Hee Un Son
Journal:  J Korean Neurosurg Soc       Date:  2014-09-30

10.  Small dose of propofol combined with dexamethasone for postoperative vomiting in pediatric Moyamoya disease patients: a prospective, observer-blinded, randomized controlled study.

Authors:  Jeongmin Kim; Gyu Dong Jang; Dong-Suk Kim; Kyeong Tae Min
Journal:  Korean J Anesthesiol       Date:  2013-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.